Option chain shows key data for Vigil Neuroscience's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Vigil Neuroscience.

Vigil Neuroscience (NASDAQ:VIGL) Stock, Option Chain

Vigil Neuroscience

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

VIGL

Biotech

News

Health Care

Movers

General

Vigil Neuroscience reports promising interim results from its Phase 1 trial of VG-3927, showing a strong safety, tolerability, and pharmacokinetic profile in healthy volunteers. The data support continued development of VG-3927 as a potential daily oral therapy for Alzheimer&#39;s disease.

Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer&#39;s Candidate Shows Significant Impact On Disease Bimarker

Earnings

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

APDN

BDSX

Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio is, the higher the stock value. The reasoning behind this is straightforward — when a stock&#39;s current market price does not adequately reflect its higher earnings, it suggests potential for growth.

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

Equities

Vigil Neuroscience Inc (NASDAQ: VIGL) shares are down after the company released interim data from its Phase 2 IGNITE proof-of-concept clinical trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a neurological condition characterized by changes to&amp;nb

Why Is Rare Neurological Disease Focused Vigil Neuroscience Stock Trading Lower Today?

Vigil Neuroscience Inc

Morgan Stanley analyst Hamza Fodderwala maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Overweight and raises the price target from $223 to $230.

Price Target

PANW

Morgan Stanley Maintains Overweight on Palo Alto Networks, Raises Price Target to $230

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst John Glass downgraded the rating for Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) from Overweight to Equal-Weight and lowered the price target from $158 to $140. Yum Brands shares closed at $125.32 on Friday. <a href="https://www.benzinga.com/quote/YUM/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Jefferies analyst Kyle Mcnealy downgraded Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from Hold to Underperform and lowered the price target from $211.84 to $200.75. Apple shares closed at $229.98 on Friday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Alex Straton downgraded Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) from Overweight to Equal-Weight and cut the price target from $164 to $140. Ross Stores shares closed at $149.15 on Friday. <a href="https://www.benzinga.com/quote/ROST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Benjamin Theurer downgraded the rating for Bunge Global SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) from Overweight to Equal-Weight and lowered the price target from $115 to $95. Bunge Global shares closed at $79.54 on Friday. <a href="https://www.benzinga.com/quote/BG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Benjamin Theurer downgraded CF Industries Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) from Overweight to Equal-Weight but raised the price target from $96 to $100. CF Industries shares closed at $97.01 on Friday. <a href="https://www.benzinga.com/quote/CF/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="564" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133-1024x564.png" alt="" class="wp-image-742291" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133-1024x564.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133-768x423.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43091705/top-4-health-care-stocks-you-may-want-to-dump-in-q1">Top 4 Health Care Stocks You May Want To Dump In Q1</a></li>
</ul>

Downgrades

Pre-Market Outlook

AAPL

ROST

This Apple Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Citigroup analyst Jason Gursky upgrades RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) from Neutral to Buy and raises the price target from $132 to $153.

Upgrades

Citigroup Upgrades RTX to Buy, Raises Price Target to $153

– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315
– Posters highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance
WEST CHESTER, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrca#NASDAQ">VRCA</a>), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the presentation of three posters that were presented at the 2025 Winter Clinical Dermatology Conference, which was held from January 17-19, in Miami, Florida. The posters featured clinical data from Part 2 of the Phase 2 study (the "Study") of the Company's novel oncolytic peptide, VP-315, for the treatment of basal cell carcinoma ("BCC").
Verrica presented a poster titled "Calculated Objective Response Rate (ORR) of 97% from Post-Hoc Analysis of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma (BCC)" while encore presentations of two additional posters (titled "Results of a Phase 2 Multicenter Study Evaluating the Safety and Tolerability of VP-315, an Investigational therapy for Basal Cell Carcinoma" and "Results of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational Therapy for Basal Cell Carcinoma") were also made at the conference. The posters included safety and histologic clearance data from 82 patients with up to two target BCC tumors (a total of 91 tumors) in Part 2 of the Study evaluating VP-315 for the treatment of BCC, including patients with tumors on the head and neck.
Part 2 of the Study was designed to explore dosing regimens to help Verrica identify the recommended regimen for a Phase 3 study program. Approximately 51% of tumors treated in the Study achieved complete histological clearance, while those patients with a residual tumor achieved, on average, approximately 71% reduction in tumor size. There were no Treatment Related Serious Adverse Events, and most Treatment Related Adverse Events were mild to moderate.
In the newly-presented poster, Verrica conducted a post-hoc analysis of the data from the Study and announced a Calculated ORR of 97%, defined as the percentage of study subjects who do not demonstrate disease progression and who experience at least a 30% level of tumor reduction along with partial or complete response following treatment The Company still expects genomic and T-cell (immune response) data in the first quarter of 2025 and plans to request an End-of-Phase 2 meeting with the FDA in the first half of 2025 to determine the next steps for the development of VP-315 for the treatment of BCC.

VRCA

Verrica Pharmaceuticals To Present 3 Posters Featuring Preliminary Topline Results Of VP-315 For The Treatment Of Basal Cell Carcinoma, Including A 97% Calculated Objective Response Rate Of Study Subjects Following Treatment With VP-315 At The 2025 Winter Clinical Dermatology Conference

<h3>Gainers</h3>
<ul>
<li>Envela (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELA#AMEX">ELA</a>) shares rose 17.7% to $8.39 during Tuesday's pre-market session. The company's market cap stands at $218.1 million. </li>
<li>Chijet Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) stock moved upwards by 14.52% to $2.01. The market value of their outstanding shares is at $14.1 million. </li>
<li>Premium Catering (Hldgs) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PC#NASDAQ">PC</a>) stock moved upwards by 11.21% to $0.8. The market value of their outstanding shares is at $12.8 million. </li>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) stock moved upwards by 9.89% to $0.53. The market value of their outstanding shares is at $7.9 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) stock rose 8.26% to $2.49. The market value of their outstanding shares is at $9.7 million. </li>
<li>Zapp Electric Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) shares moved upwards by 8.03% to $1.21. The company's market cap stands at $5.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Canoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) stock declined by 73.4% to $0.36 during Tuesday's pre-market session. The company's market cap stands at $5.1 million. </li>
<li>New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) stock declined by 12.56% to $53.2. The market value of their outstanding shares is at $8.6 billion. The company's, Q2 earnings came out today. </li>
<li>AYRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) stock fell 8.91% to $0.64. The company's market cap stands at $4.3 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) stock declined by 8.36% to $0.67. The market value of their outstanding shares is at $14.1 million. </li>
<li>Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) shares fell 6.59% to $126.6. The market value of their outstanding shares is at $34.7 billion. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) stock decreased by 6.49% to $2.74. The company's market cap stands at $9.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALUR

AYRO

CJET

New Oriental Education & Technology Group

GDHG

GOEV

VEEE

ZAPP

12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock rose 47.8% to $1.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.1 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares increased by 36.89% to $2.56. The market value of their outstanding shares is at $3.4 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares rose 19.82% to $1.39. The market value of their outstanding shares is at $3.8 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock increased by 19.75% to $6.75. The company's market cap stands at $8.6 million. </li>
<li>Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) shares rose 19.14% to $41.88. The company's market cap stands at $6.5 billion. </li>
<li>Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) stock rose 17.39% to $5.94. The company's market cap stands at $336.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares declined by 14.1% to $7.6 during Tuesday's pre-market session. The market value of their outstanding shares is at $276.3 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares fell 12.47% to $0.13. The market value of their outstanding shares is at $10.7 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock decreased by 10.94% to $0.57. The company's market cap stands at $10.4 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock fell 10.64% to $2.52. The market value of their outstanding shares is at $124.9 million. </li>
<li>Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) shares fell 9.76% to $1.11. The company's market cap stands at $47.7 million. </li>
<li>Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) stock decreased by 9.1% to $310.0. The company's market cap stands at $8.8 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

AKYA

BDMD

BMRA

DSGN

DWTX

HSDT

RDHL

RPID

TNFA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Innovate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) shares increased by 22.5% to $6.26 during Tuesday's pre-market session. The market value of their outstanding shares is at $83.0 million. </li>
<li>Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) stock moved upwards by 10.64% to $16.32. The market value of their outstanding shares is at $1.0 billion. </li>
<li>Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) shares moved upwards by 9.69% to $4.3. The company's market cap stands at $212.2 million. </li>
<li>ACCO Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACCO#NYSE">ACCO</a>) shares rose 9.42% to $5.69. The market value of their outstanding shares is at $544.1 million. </li>
<li>Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) shares increased by 7.44% to $3.61. The company's market cap stands at $399.1 million. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares increased by 6.97% to $0.44. The company's market cap stands at $10.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Graphex Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#AMEX">GRFX</a>) stock decreased by 15.9% to $0.26 during Tuesday's pre-market session. The company's market cap stands at $15.2 million. </li>
<li>Nocera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCRA#NASDAQ">NCRA</a>) stock declined by 8.26% to $1.0. The market value of their outstanding shares is at $14.0 million. </li>
<li>SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares decreased by 6.46% to $0.87. The company's market cap stands at $311.1 million. </li>
<li>Staffing 360 Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) shares fell 5.94% to $3.17. The company's market cap stands at $4.8 million. </li>
<li>Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) shares decreased by 5.71% to $2.81. The market value of their outstanding shares is at $152.2 million. </li>
<li>Multi Ways Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MWG#AMEX">MWG</a>) stock decreased by 5.58% to $0.27. The market value of their outstanding shares is at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACCO

AMPX

BAER

CRGO

GRFX

NCRA

PSIG

STAF

VATE

12 Industrials Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>X3 Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) stock rose 19.9% to $1.19 during Tuesday's pre-market session. The market value of their outstanding shares is at $16.3 million. </li>
<li>Logility Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGTY#NASDAQ">LGTY</a>) shares increased by 12.52% to $12.4. The company's market cap stands at $417.6 million. </li>
<li>Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) stock moved upwards by 10.44% to $2.22. The company's market cap stands at $638.7 million. </li>
<li>SatixFy Communications (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SATX#AMEX">SATX</a>) stock increased by 9.85% to $1.56. The market value of their outstanding shares is at $130.3 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock moved upwards by 9.59% to $8.45. The market value of their outstanding shares is at $130.3 million. </li>
<li>WISeKey Intl Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) stock increased by 8.69% to $8.0. The market value of their outstanding shares is at $89.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) stock decreased by 25.0% to $0.84 during Tuesday's pre-market session. The company's market cap stands at $19.4 million. </li>
<li>BTC Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) stock decreased by 10.9% to $7.36. The market value of their outstanding shares is at $38.6 million. </li>
<li>PicoCELA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCLA#NASDAQ">PCLA</a>) stock declined by 10.08% to $2.32. The market value of their outstanding shares is at $57.2 million. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) stock declined by 8.5% to $0.86. </li>
<li>CISO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) stock declined by 7.77% to $0.95. The company's market cap stands at $11.2 million. </li>
<li>Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) stock declined by 6.84% to $12.0. The company's market cap stands at $50.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTCT

CISO

INLX

LGTY

ORKT

PCLA

SatixFy Communications Ltd. Ordinary Share

SATX

SOBR

WKEY

XTKG

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

Old National Bancorp Reported Q4 Return On Average Tangible Common Equity Of 16.4%; Adjusted Of 17.0%, With Preliminary Regulatory Tier 1 Common Equity To Risk-weighted Assets Of 11.38%, Up 38 BPS

Needham analyst Ryan Koontz reiterates Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) with a Buy and maintains $5.5 price target.

Reiteration

LTRX

Needham Reiterates Buy on Lantronix, Maintains $5.5 Price Target

Contracts

GILT

Gilat Bags $5M To Improve Defense Forces Connectivity

Citigroup analyst Jason Gursky initiates coverage on V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) with a Buy rating and announces Price Target of $64.

Initiation

Citigroup Initiates Coverage On V2X with Buy Rating, Announces Price Target of $64

Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.46 by 6.52 percent. This is a 6.52 percent increase over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $489.95 million which beat the analyst consensus estimate of $485.57 million by 0.90 percent. This is a 5.48 percent increase over sales of $464.50 million the same period last year.

Old National Q4 2024 Adj EPS $0.49 Beats $0.46 Estimate, Sales $489.95M Beat $485.57M Estimate

Guaranty Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNTY#NYSE">GNTY</a>) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.61 by 42.62 percent. This is a 70.59 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $31.90 million which beat the analyst consensus estimate of $29.49 million by 8.17 percent. This is a 11.50 percent increase over sales of $28.61 million the same period last year.

Earnings Beats

GNTY

Guaranty Bancshares Q4 EPS $0.87 Beats $0.61 Estimate, Sales $31.90M Beat $29.49M Estimate

WIIM

3M shares are trading higher following better-than-expected Q4 EPS and revenues.

Needham analyst Ryan Koontz reiterates AudioCodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUDC#NASDAQ">AUDC</a>) with a Buy and maintains $11 price target.

AUDC

Needham Reiterates Buy on AudioCodes, Maintains $11 Price Target

Citigroup analyst Jason Gursky upgrades Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) from Neutral to Buy and maintains the price target from $587 to $587.

Citigroup Upgrades Northrop Grumman to Buy, Maintains Price Target to $587

SCLX

Scilex Holding Company Will File Supplemental New Drug Application With FDA For ELYXYB In Acute Pain Indication

Under a contract with an innovative space systems prime contractor, Mercury will deliver a number of these subsystems that leverage its commercial products and deep expertise in data recording, data processing, and subsystem integration for defense applications. The solution features Mercury's <a href="https://www.globenewswire.com/Tracker?data=hFuWPOlGyHW_IcBrSBkyAFrswkTsiBadnTfNZQc9-_AQkVZ8Gp9emKme31OZuQ_9xTen66IHSRGwoMRHniW6Swmkml8YIaKQBOkRIAgNbJecCVfvMlTs1rf10LJo2QesgZn_uQW5FxKcsQSKCVBabw==">SCFE6933</a> processing board that employs AMD Versal&#x2122; AI Core series FPGAs and the company's new <a href="https://www.globenewswire.com/Tracker?data=rp1OLHIt8VBlygFKl5wxzxxOTq7iF5Jy-yzJdnjFMDaBQ8feKSOWg3jJZvuqTGT5A4dwNEzuCXrPkuoM1P46895zJ9z277wsLwIefJvb0nRHBbAwLNsaxy8W0baE1Ytr0aPPY6Blav4TrgcPk0n1kL3pwSs4IPJLbW0-ZDOSXsE=">RH304T</a> solid-state data recorder, a radiation-tolerant 3U device with 4.5 terabytes of capacity.

MRCY

Mercury Systems Secures $24.5M Contract For Data Processing Subsystem In U.S. Satellite Program

Needham analyst Ryan Koontz reiterates Viasat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) with a Buy and maintains $19 price target.

VSAT

Needham Reiterates Buy on Viasat, Maintains $19 Price Target

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vigil Neuroscience Inc (VIGL – Research Report), Qiagen (QGEN – R...

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Qiagen (QGEN) and LifeMD (LFMD)

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on VIGL stock, giving a Buy rating on November 8. Graig Suvannavejh...

Bullish Outlook on Vigil Neuroscience Inc. Amid Promising Clinical Data and Unique TREM2 Biology Focus

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report), Vigil Neuroscience Inc (...

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Vigil Neuroscience Inc (VIGL) and Biohaven Ltd. (BHVN)

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated price ta...

Promising Potential of Vigil Neuroscience's VG-3927 in Alzheimer's Treatment with a Buy Rating and $17 Price Target

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on VIGL stock, giving a Buy rating yesterday. Graig Suvannavejh has...

Optimistic Buy Rating for Vigil Neuroscience Amid Market Overreaction

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IN8bio (INAB – Research Report), Vigil Neuroscience ...

Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Vigil Neuroscience Inc (VIGL) and Outlook Therapeutics (OTLK)

Vigil Neuroscience: Down On A Competitor's Failure

William Blair analyst Sarah Schram initiated coverage of Vigil Neuroscience (VIGL) with an Outperform rating. Published first on TheFly – the ultim...

Vigil Neuroscience initiated with an Outperform at William Blair

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Terns Pharmaceuticals (TERN – Research Report), Trev...

Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN), Trevi Therapeutics (TRVI) and Vigil Neuroscience Inc (VIGL)

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on VIGL stock, giving a Buy rating on December 3. Graig Suvannavejh...

Comments

Vigil Neuroscience

Vigil Neuroscience (VIGL) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga